These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 23228446)

  • 1. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
    Galsky MD; Hahn NM; Powles T; Hellerstedt BA; Lerner SP; Gardner TA; Yu M; O'Rourke M; Vogelzang NJ; Kocs D; McKenney SA; Melnyk AM; Hutson TE; Rauch M; Wang Y; Asmar L; Sonpavde G
    Clin Genitourin Cancer; 2013 Jun; 11(2):175-81. PubMed ID: 23228446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
    Narayan V; Mamtani R; Keefe S; Guzzo T; Malkowicz SB; Vaughn DJ
    Cancer Res Treat; 2016 Jul; 48(3):1084-91. PubMed ID: 26639198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
    Geldart T; Chester J; Casbard A; Crabb S; Elliott T; Protheroe A; Huddart RA; Mead G; Barber J; Jones RJ; Smith J; Cowles R; Evans J; Griffiths G
    Eur Urol; 2015 Apr; 67(4):599-602. PubMed ID: 25465968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
    Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
    Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
    Vogelzang NJ
    J Clin Oncol; 2013 Feb; 31(6):670-5. PubMed ID: 23341524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
    Weight CJ; Garcia JA; Hansel DE; Fergany AF; Campbell SC; Gong MC; Jones JS; Klein EA; Dreicer R; Stephenson AJ
    Cancer; 2009 Feb; 115(4):792-9. PubMed ID: 19127557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.
    Niedersüss-Beke D; Puntus T; Kunit T; Grünberger B; Lamche M; Loidl W; Böhm R; Kraischits N; Kudlacek S; Schramek P; Meran JG
    Oncology; 2017; 93(1):36-42. PubMed ID: 28399521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
    Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
    Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
    Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
    Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
    Meleis L; Moore R; Inman BA; Harrison MR
    J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
    Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
    Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
    Schinzari G; Monterisi S; Pierconti F; Nazzicone G; Marandino L; Orlandi A; Racioppi M; Cassano A; Bassi P; Barone C; Rossi E
    Anticancer Res; 2017 Nov; 37(11):6453-6458. PubMed ID: 29061832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies.
    Cho SW; Lim SH; Kwon GY; Kim CK; Park W; Pyo H; Chung JH; Song W; Sung HH; Jeong BC; Park SH
    Cancer Res Treat; 2024 Jul; 56(3):893-897. PubMed ID: 38374699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
    J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.
    Hussain SA; Stocken DD; Riley P; Palmer DH; Peake DR; Geh JI; Spooner D; James ND
    Br J Cancer; 2004 Aug; 91(5):844-9. PubMed ID: 15292922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
    Choudhury A; Swindell R; Logue JP; Elliott PA; Livsey JE; Wise M; Symonds P; Wylie JP; Ramani V; Sangar V; Lyons J; Bottomley I; McCaul D; Clarke NW; Kiltie AE; Cowan RA
    J Clin Oncol; 2011 Feb; 29(6):733-8. PubMed ID: 21205754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).
    Sternberg CN; Skoneczna IA; Castellano D; Theodore C; Blais N; Voog E; Bellmunt J; Peters F; Le-Guennec S; Cerbone L; Risse ML; Machiels JP
    Oncology; 2013; 85(4):208-15. PubMed ID: 24080920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
    Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
    Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
    Lin CC; Hsu CH; Huang CY; Keng HY; Tsai YC; Huang KH; Cheng AL; Pu YS
    Anticancer Drugs; 2007 Apr; 18(4):487-91. PubMed ID: 17351402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.